Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Suramin sodium - Bayer

Drug Profile

Suramin sodium - Bayer

Alternative Names: Antrypol; Bayer 205; CI 1003; Germanin; Metaret; Moranyl; Suramin; Suramin hexasodium

Latest Information Update: 28 Jan 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer
  • Developer Austrian Academy of Sciences; Bayer; National Cancer Institute (USA); Optimum Therapeutics; Pfizer; The First Affiliated Hospital of Zhengzhou University; University of California, San Diego; University of Wisconsin-Madison
  • Class Antiprotozoals; Behavioural disorder therapies; Naphthalenesulfonates
  • Mechanism of Action DNA-directed DNA polymerase inhibitors; Intercellular signalling peptide and protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Enterovirus A infections
  • Discontinued Atherosclerosis; Bladder cancer; Breast cancer; Cancer pain; HIV infections; Non-small cell lung cancer; Pervasive child development disorders; Prostate cancer; Vascular restenosis

Most Recent Events

  • 28 Jan 2022 No recent reports of development identified for phase-I development in Enterovirus A infections(In volunteers) in China (IV)
  • 08 Apr 2021 Discontinued - Phase-I/II for Pervasive child development disorders in USA (IV) (NCT02508259)
  • 08 Apr 2021 Discontinued - Phase-II for Non-small cell lung cancer in USA (IV) (NCT01038752)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top